obrixtamig

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)Neuroendocrine NeoplasmsSmall Cell Lung Cancer (SCLC)Small Cell Lung Carcinoma (SCLC)

Phase 1

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Active, not recruitingNCT05879978

Boehringer IngelheimNeuroendocrine Neoplasms, Small Cell Lung Carcinoma (SCLC)

Start: 2023-06-27End: 2026-06-30Updated: 2026-04-02

Phase 3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Not yet recruitingNCT07472517

Boehringer IngelheimExtensive-stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)

Start: 2026-04-10End: 2029-07-31Target: 670Updated: 2026-03-31